PTC Therapeutics Inc. (PTCT)
PTCT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1070081/000110465926017575/0001104659-26-017575-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | PTCT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2013 |
| SEC CIK | 0001070081 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.7B |
| Net income | $682.6M |
| Operating income | $866.9M |
| Net margin | 39.4% |
| Operating margin | 50.1% |
| Revenue growth | +114.5% |
| Cash | $984.6M |
| Total assets | $2.9B |
| P/E (computed) | 7.5× |
| P/S (computed) | 2.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-29 |
| Cash and burn | $508.9M cash; operating cash flow $2.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 83,544,284 (2026-10-27); 80,288,305 a year earlier; 75,463,145 three years earlier. | Cover page 2026-10-27 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Iselin, New Jersey, United States | PCAOB Form AP 2026-03-04 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $64.6M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $357.8M | -$51.7M | -$25.3M | $508.9M | $536.3M | $1.2B | 10-Q 2026-10-29 |
| Q2 2026 2026-06-30 | $360.5M | $83.5M | $129.1M | $1.0B | $591.0M | $1.0B | 10-Q 2026-07-30 |
| Q1 2026 2026-03-31 | $272.6M | -$2.8M | -$59.0M | $834.0M | $286.9M | $827.1M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $164.7M | -$135.0M | -$34.3M | $984.6M | $286.6M | $1.7B | 10-K 2026-02-19 |
| Q3 2025 2025-09-30 | $211.0M | $15.9M | -$66.3M | $672.6M | $286.3M | $1.8B | 10-Q 2026-10-29 |
| Q2 2025 2025-06-30 | $178.9M | -$64.8M | -$58.3M | $1.0B | $286.0M | $1.8B | 10-Q 2026-07-30 |
| Q1 2025 2025-03-31 | $1.2B | $866.6M | $870.1M | $1.5B | $285.7M | $1.8B | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $213.2M | -$65.9M | -$30.0M | $779.7M | $285.4M | $806.8M | 10-K 2026-02-19 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2023-05-05 |
| Latest annual report | 10-K | 2026-02-19 |
| Latest quarterly / interim | 10-Q | 2026-10-29 |
| Latest current report | 8-K | 2026-11-03 |
| Latest proxy | DEFA14A | 2026-04-20 |
Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -3.0% |
| 1 month | +6.0% |
| 3 months | -11.8% |
| Year to date | -16.4% |
| 1 year | -15.3% |
| From 52-week high | -29.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| LQDA | Liquidia Corporation | $56.37 | -1.81% | $5.1B |
| DNTH | Dianthus Therapeutics Inc. | $89.55 | -2.46% | $5.0B |
| ERAS | Erasca Inc. | $15.11 | -3.51% | $5.3B |
| MANE | Veradermics Incorporated | $128.05 | -1.24% | $5.4B |
| EWTX | Edgewise Therapeutics Inc. | $43.68 | -4.90% | $4.8B |
| COGT | Cogent Biosciences Inc. | $27.44 | -3.92% | $4.8B |
| TVTX | Travere Therapeutics Inc. | $49.70 | -1.88% | $4.8B |
| IONS | Ionis Pharmaceuticals Inc. | $28.01 | -3.61% | $4.7B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier